Effects of GSH and WR-2721 on induction of micronuclei by cyclophosphamide

Toxicology Letters

Volumn 110, Issue 1-2, 1999, Pages 67-72

  Mazur, Lidia ^a   Blawat, Aneta ^a  

^a Department of Animal Physiology   (Poland)

Author keywords

'Delayed apoptosis'; Chemoprotection; Cyclophosphamide (CP); Cytotoxicity; Micronuclei; Reduced glutathione (GSH); S 2 (3 Aminopropylamino)ethyl phosphorothioic acid (WR 2721)

Indexed keywords

AMIFOSTINE; CYCLOPHOSPHAMIDE; GLUTATHIONE; THIOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL COUNT; CELL PROTECTION; CYTOTOXICITY; ERYTHROCYTE; GENOTOXICITY; MALE; MICRONUCLEUS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACRIDINE ORANGE; AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BONE MARROW CELLS; CYCLOPHOSPHAMIDE; DRUG SYNERGISM; ERYTHROCYTES; FLUORESCENT DYES; GLUTATHIONE; MALE; MICE; MICRONUCLEUS TESTS;

ANIMALIA;

EID: 0032692470     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(99)00139-3     Document Type: Article

References (27)

1. Alberts D.S., Bleyer A. Future development of Amifostine in cancer treatment. Semin. Oncol. 23:1996;90-99.
2. Brookes P. The early history of the biological alkylating agents. Mutat. Res. 233:1990;3-14.
3. Budd G.T., Lorenzi V., Ganapathi R., Adelstein D., Pelley R., Olencki T., McLain D., Bukowski R.M. Amifostine: potential for clinically useful cytoprotection. Support. Care. Cancer. 2:1994;380-384.
4. Capizzi R.L. Protection of normal tissues from the cytotoxic effects of chemotherapy by Amifostine (Ethyol): clinical experiences. Semin. Oncol. 21:1994;8-15.
5. Darzynkiewicz Z., Juan G., Li X., Gorczyca W., Murakami T., Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry. 27:1997;1-20.
6. Donnerstag B., Ohlenschlager B., Cinatl J., Hofmann D., Flindt S., Treusch G., Träger L. Reduced glutathione and S-acetylglutathione as selective apoptosis-inducing agents in cancer therapy. Cancer Lett. 110:1996;63-70.
7. Ferguson L.R., Pearson A.E. The clinical use of mutagenic anticancer drugs. Mutat. Res. 355:1966;1-12.
8. Fraiser L.H., Kanekal S., Kehrer J.P. Cyclophosphamide toxicity. Drugs. 42:1991;781-795.
9. Griggs J.J. Reducing the toxicity of anticancer therapy: new strategies. Leukemia Res. 1001:1998;27-33.
10. Hayashi M., Sofuni T., Ishidate M. Jr An application of acridine orange fluorescent staining to the micronucleus test. Mutat. Res. 120:1983;241-247.
11. Kurbacher C.M., Mallmann P.K. Chemoprotection in anticancer therapy: the emerging role of Amifostine (WR-2721). Anticancer Res. 18:1998;2203-2210.
12. Mavournin K.H., Blakey D.H., Cimino M.C., Salamone M.F., Heddle J.A. The in vivo micronucleus assay in mammalian bone marrow and peripheral blood. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat. Res. 239:1990;29-80.
13. Mazur L. Induction of micronucleated erythrocytes by MEA, AET, WR-2721 and X-rays. Mutat. Res. 334:1995;317-322.
14. Mazur L., Darzynkiewicz Z. Apoptoza w ukladzie hemopoetycznym (Apoptosis in the Haemopoietic System). Dabrowski Z. Fizjologia krwi (Physiology of Blood). 1998;268-315 PWN, Warszawa.
15. Meister A. Glutathione, ascorbate, and cellular protection. Cancer Res. 54:1994;1969-1975.
16. Mesner P.W., Budihardjo I.I., Kaufmann S.H. Chemotherapy-induced apoptosis. Adv. Pharmacol. 41:1997;461-499.
17. Moore M.J. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 20:1991;194-208.
18. Müller W.U., Streffer C. Micronucleus assay. Obe G. Advances in Mutagenesis Research. 5:1994;4-134 Springer-Verlag, Berlin.
19. Schuchter L.M., Luginbuhl W.E., Meropol N.J. The current status of toxicity protectants in cancer therapy. Semin. Oncol. 19:1992;742-751.
20. Shaw L.M., Bonner H., Lieberman R. Pharmacokinetic profile of Amifostine. Semin. Oncol. 23:1996;18-22.
21. Smith C.V., Jones D.P., Guenthner T.M., Lash L.H., Lauterburg B.H. Compartmentation of glutathione: implications for the study of toxicity and disease. Toxicol. Appl. Pharmacol. 140:1996;1-12.
22. Spencer C.M., Goa K.L. Amifostine. A review of its pharmacodynamic and pharmacokinetics properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs. 50:1995;1001-1031.
23. Stewart F.A. Modification of normal tissue response to radiotherapy and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 16:1989;1195-1200.
24. Sugimoto C., Matsukawa S., Fujieda S., Noda I., Tanaka N., Tsuzuki H., Saito H. Involvement of intracellular glutathione in induction of apoptosis by cisplatin in a human pharyngeal carcinoma cell line. Anticancer Res. 16:1996;675-680.
25. Uma Devi P. Normal tissue protection in cancer therapy - progress and prospects. Acta Oncol. 37:1998;247-252.
26. Utley J.F., Seaver N., Newton G.L., Fathey R.C. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int. J. Radiat. Oncol. Biol. Phys. 10:1984;1525-1528.
27. Van der Vijgh W.J.F., Peters G.J. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by Amifostine (Ethyol): preclinical aspects. Semin. Oncol. 21:1994;2-7.